ArticleFrontiers in endocrinology2026
Roundup
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glyphosate-based herbicides (GBHs), such as Roundup®, are ubiquitous environmental contaminants with emerging endocrine-disrupting properties. Based on previous findings of non-monotonic effects in thyroid models, this study investigated lineage-dependent cytotoxic and proliferative responses to Roundup® in thyroid cells with different cytogenic profiles. Methods: Human papillary carcinoma (BCPAP, BRAFV600E) and anaplastic carcinoma (8505C) cells were exposed to Roundup® Original DI (6.5-6500 µg/L) for 24 and 48 hours. Cell viability was assessed using trypan blue exclusion and CCK-8 assays, and proliferation was measured by BrdU incorporation. The data were integrated with previous results from normal (Nthy-ori 3-1) and papillary (TPC-1) cell lines for comparative analysis. Results: Exposure to Roundup® induced specific effects for each cell type. The BCPAP cell line demonstrated significant sensitivity, with reduced viability and sustained proliferative stimulation at low concentrations. In contrast, anaplastic 8505C cells proved to be highly resistant, exhibiting transient biphasic proliferation and recovery of viability even at high doses. A consolidated analysis established a clear hierarchy of sensitivity: TPC-1 > BCPAP > Nthy-ori3-1 > 8505C, revealing that papillary thyroid carcinoma cells are the most vulnerable. Crucially, a concentration of 65 µg/L, which is below current regulatory limits, triggered proliferative responses in all cell models. Discussion: These results suggest that Roundup® is a potent endocrine disruptor that exerts mutation-specific proliferative effects on thyroid cancer cells. Consistent growth stimulation at low, environmentally relevant doses suggests a potential tumor-promoting role, particularly in papillary carcinomas driven by the MAPK pathway. This evidence reinforces the need to revise risk assessments of GBHs (subcutaneous hypothyroidism) to take into account endocrine disruption and the potential for cancer progression beyond traditional toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.